CA
NZ
UK
AU
IND
US
Nasdaq issued a Staff Delisting Determination on October 13, 2026, and the company appealed the next day, which stays any delisting while a Hearings Panel reviews the matter. Shareholders approved a share consolidation on October 30, 2026. Half-yearRevenuerose 34 percent to USD 24.0 million. …
The latest release was the October 20, 2026 closing of a USD 3.75 million registered direct offering. First half 2026Revenuewas USD 12.94 million, up 26.01 percent, and the company completed 1-for-16 and 1-for-200 share combinations this year. The shares trade far below the USD …
In the efficacy population, 7 of 26 patients, or 27 percent, had no surgical papilloma removal over 12 months. The company expects a full commercial launch in the first quarter of 2027, and the FDA requires a draft confirmatory study protocol by the end …
Shareholders approved a share consolidation on October 30, 2026, with the ratio reported to have been raised from 20 for one to 100 for one. Half-year net loss was USD 18.5 million. Cash of about USD 767 thousand against a stockholders'Deficitof about USD 20.6 …
In the efficacy population, 7 of 26 patients, or 27 percent, had no surgical papilloma removal over 12 months. The company expects shipping in about 60 days. Cash was USD 36.7 million at June 30, 2026, excluding USD 18.3 million of net July offering …
No new company announcement dated November 2, 2026 was identified. The most relevant recent event is the expiry of a creditor forbearance period on November 1, 2026, the final calendar day before this session opened.
Net loss narrowed sharply, yet the shares still traded lower. AdjustedNet Incomewas USD 35 million, or USD 0.06 per share, so the market reaction may reflect the reportedGAAPloss and the heavy debt load rather than any single operating miss.
Sub-USD 1 shares with limitedLiquiditycan move sharply on small volumes, and the pre-market price sits below the USD 1.00 level at which the company sold its ADSs in June 2026. That gap may be influencing sentiment, though this is an observation rather than a …
Jiayin Group (NASDAQ:JFIN) was down 6.17 percent to USD 1.52 in pre-market trading on November 2, 2026. No company announcement explaining the move was identified for late October or November 2, 2026.
No company press release or regulatory filing explaining the move was identified. The pattern points to sentiment and thin trading rather than a disclosed catalyst.
Please wait processing your request...